T cells and adaptive immunity to Mycobacterium tuberculosis in humans

Immunological Reviews

Volumn 264, Issue 1, 2015, Pages 74-87

  Jasenosky, Luke D ^a   Scriba, Thomas J ^b   Hanekom, Willem A ^b,c   Goldfeld, Anne E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

CD4+; CD8+; HIV co infection; IL 10 producing immunosuppressive and Treg cells; TB; Th1 and Th17 cells

Indexed keywords

BCG VACCINE; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR6; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERSTITIAL COLLAGENASE; STROMELYSIN; TUMOR NECROSIS FACTOR; CYTOKINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION CONTROL; LUNG LAVAGE; MACROPHAGE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; METABOLISM; MICROBIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ADAPTIVE IMMUNITY; BCG VACCINE; COINFECTION; CYTOKINES; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTE SUBSETS; TUBERCULOSIS;

EID: 84923197606     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12274     Document Type: Article

References (210)

1. Yang H, Kruh-Garcia NA, Dobos KM. Purified protein derivatives of tuberculin-past, present, and future. FEMS Immunol Med Microbiol 2012;66:273-280.
2. Wallgren A. The time-table of tuberculosis. Tubercle 1948;29:245-251.
3. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-686.
4. Millington KA, Gooding S, Hinks TS, Reynolds DJ, Lalvani A. Mycobacterium tuberculosis-specific cellular immune profiles suggest bacillary persistence decades after spontaneous cure in untreated tuberculosis. J Infect Dis 2010;202:1685-1689.
5. Esmail H, Barry CE 3rd, Young DB, Wilkinson RJ. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 2014;369:20130437.
6. Sousa AO, et al. An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon. Proc Natl Acad Sci USA 1997;94:13227-13232.
7. Boussiotis VA, et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000;105:1317-1325.
8. Delgado JC, et al. Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia. Proc Natl Acad Sci USA 2002;99:7576-7581.
9. Cobat A, et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J Exp Med 2009;206:2583-2591.
10. Delgado JC, Quinones-Berrocal J, Thim S, Miranda LF, Goldfeld AE. Diagnostic and clinical implications of response to tuberculin in two ethnically distinct populations from Peru and Cambodia. Int J Tuberc Lung Dis 2004;8:982-987.
11. Baliko Z, Szereday L, Szekeres-Bartho J. Th2 biased immune response in cases with active Mycobacterium tuberculosis infection and tuberculin anergy. FEMS Immunol Med Microbiol 1998;22:199-204.
12. Thye T, et al. IL10 haplotype associated with tuberculin skin test response but not with pulmonary TB. PLoS ONE 2009;4:e5420.
13. + T cell population, apoptosis and enhanced inhibitory cytokine production. PLoS ONE 2013;8:e71245.
14. Szereday L, Baliko Z, Szekeres-Bartho J. Gamma/delta T cell subsets in patients with active Mycobacterium tuberculosis infection and tuberculin anergy. Clin Exp Immunol 2003;131:287-291.
15. Zembrzuski VM, et al. Cytokine genes are associated with tuberculin skin test response in a native Brazilian population. Tuberculosis 2010;90:44-49.
16. Lindenau JD, et al. Cytokine gene polymorphisms are associated with susceptibility to tuberculosis in an Amerindian population. Int J Tuberc Lung Dis 2014;18:952-957.
17. Lindenau JD, et al. Association between HLA-DR4 haplotypes and tuberculin skin test response in the Ache population. Tissue Antigens 2014;84:479-483.
18. Delgado JC, Baena A, Thim S, Goldfeld AE. Aspartic acid homozygosity at codon 57 of HLA-DQ beta is associated with susceptibility to pulmonary tuberculosis in Cambodia. J Immunol 2006;176:1090-1097.
19. Opie EL, Aronson JD. Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculous lesions. Arch Path & Lab Med 1927;4:1-21.
20. Keane J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
21. Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2:CD008794.
22. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 2005;11:S33-S44.
23. Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Ann Rev Pathol 2012;7:353-384.
24. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129.
25. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012;12:581-591.
26. Gupta A, Kaul A, Tsolaki AG, Kishore U, Bhakta S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 2012;217:363-374.
27. Wiker HG, Mustafa T, Bjune GA, Harboe M. Evidence for waning of latency in a cohort study of tuberculosis. BMC Infect Dis 2010;10:37.
28. Wood R, Lawn SD, Caldwell J, Kaplan R, Middelkoop K, Bekker LG. Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS ONE 2011;6:e25098.
29. Charalambous S, et al. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2008;12:942-948.
30. Crampin AC, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010;24:417-426.
31. van Rie A, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-1179.
32. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687-1693.
33. Hawn TR, et al. TB vaccines and prevention of infection. Microb Mol Biol Rev 2014;78:650-671.
34. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, Vynnycky E. Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 1999;3:962-975.
35. Adams JM, Kalajan VA, Mork BO, Rosenblatt M, Rothrock WJ, O'Loughlin BJ. Reversal of tuberculin reaction in early tuberculosis. Dis Chest 1959;35:348-356.
36. Hill PC, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007;4:e192.
37. Machingaidze S, et al. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012;186:1051-1056.
38. Dahlstrom AW. The instability of the tuberculin reaction. Am Rev Turberc 1940;42:471-487.
39. Andrews JR, et al. The dynamics of QuantiFERON-TB Gold In-Tube convesion and reversion in a cohort of South African adolescents. Am J Respir Crit Care Med 2015, in press.
40. Khader SA, et al. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 2006;203:1805-1815.
41. Wolf AJ, et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 2008;205:105-115.
42. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 2002;70:4501-4509.
43. Wolf AJ, et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007;179:2509-2519.
44. Srivastava S, Ernst JD. Cell-to-cell transfer of M. tuberculosis antigens optimizes CD4 T cell priming. Cell Host Microbe 2014;15:741-752.
45. Rajalingam R, Mehra NK, Jain RC, Myneedu VP, Pande JN. Polymerase chain reaction-based sequence-specific oligonucleotide hybridization analysis of HLA class II antigens in pulmonary tuberculosis: relevance to chemotherapy and disease severity. J Infect Dis 1996;173:669-676.
46. Pospelov LE, et al. Association of various genetic markers with tuberculosis and other lung diseases in Tuvinian children. Tuber Lung Dis 1996;77:77-80.
47. Brahmajothi V, et al. Association of pulmonary tuberculosis and HLA in south India. Tubercle 1991;72:123-132.
48. Khomenko AG, Litvinov VI, Chukanova VP, Pospelov LE. Tuberculosis in patients with various HLA phenotypes. Tubercle 1990;71:187-192.
49. Bothamley GH, et al. Association of tuberculosis and M. tuberculosis-specific antibody levels with HLA. J Infect Dis 1989;159:549-555.
50. Singh SP, Mehra NK, Dingley HB, Pande JN, Vaidya MC. Human leukocyte antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association with HLA-DR types. J Infect Dis 1983;148:676-681.
51. Kettaneh A, Seng L, Tiev KP, Toledano C, Fabre B, Cabane J. Human leukocyte antigens and susceptibility to tuberculosis: a meta-analysis of case-control studies. Int J Tuberc Lung Dis 2006;10:717-725.
52. Singh M, Balamurugan A, Katoch K, Sharma SK, Mehra NK. Immunogenetics of mycobacterial infections in the North Indian population. Tissue Antigens 2007;69(Suppl 1):228-230.
53. Ravikumar M, et al. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India. Tuber Lung Dis 1999;79:309-317.
54. Goldfeld AE, et al. Association of an HLA-DQ allele with clinical tuberculosis. J Am Med Assoc 1998;279:226-228.
55. Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001;193:271-280.
56. + T cell immunity. J Immunol 2014;192:2120-2132.
57. Lin PL, et al. CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Res Hum Retroviruses 2012;28:1693-1702.
58. Chen CY, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 2009;5:e1000392.
59. Rossouw M, Nel HJ, Cooke GS, van Helden PD, Hoal EG. Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene. Lancet 2003;361:1871-1872.
60. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-258.
61. Jeong YH, et al. Differentiation of antigen-specific T cells with limited functional capacity during Mycobacterium tuberculosis infection. Infect Immun 2014;82:132-139.
62. Chiacchio T, et al. Higher frequency of T-cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. PLoS ONE 2011;6:e27539.
63. Pollock KM, et al. T-cell immunophenotyping distinguishes active from latent tuberculosis. J Infect Dis 2013;208:952-968.
64. + T cell responses discriminate between latent infection and active disease. Nat Med 2011;17:372-376.
65. Day CL, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 2011;187:2222-2232.
66. Petruccioli E, et al. IFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis. J Infect 2013;66:475-486.
67. Riou C, et al. A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversion. PLoS ONE 2014;9:e102178.
68. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 2009;39:723-729.
69. Qiu Z, et al. Multifunctional CD4 T cell responses in patients with active tuberculosis. Sci Rep 2012;2:216.
70. + multifunctional memory T cells coexpress GM-CSF. Cytokine 2008;43:143-148.
71. Caccamo N, et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010;40:2211-2220.
72. Young JM, Adetifa IM, Ota MO, Sutherland JS. Expanded polyfunctional T cell response to mycobacterial antigens in TB disease and contraction post-treatment. PLoS ONE 2010;5:e11237.
73. Kagina BM, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010;182:1073-1079.
74. Kumar NP, et al. Expansion of pathogen-specific mono- and multifunctional Th1 and Th17 cells in multi-focal tuberculous lymphadenitis. PLoS ONE 2013;8:e57123.
75. + T-cells correlate with the magnitude of the QuantiFERON(R) gold in-tube response in a prospective study of healthy indian adolescents. PLoS ONE 2014;9:e101224.
76. Streitz M, et al. Loss of receptor on tuberculin-reactive T-cells marks active pulmonary tuberculosis. PLoS ONE 2007;2:e735.
77. Commandeur S, et al. Double- and monofunctional CD4(+) and CD8(+) T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol 2011;41:2925-2936.
78. Li L, Qiao D, Fu X, Lao S, Zhang X, Wu C. Identification of Mycobacterium tuberculosis-specific Th1, Th17 and Th22 cells using the expression of CD40L in tuberculous pleurisy. PLoS ONE 2011;6:e20165.
79. Wang X, et al. Association of mycobacterial antigen-specific CD4(+) memory T cell subsets with outcome of pulmonary tuberculosis. J Infect 2010;60:133-139.
80. + T cells at sites of pleural TB. Tuberculosis 2011;91:224-230.
81. + T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis. PLoS ONE 2012;7:e36046.
82. Arlehamn CS, et al. Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ). J Immunol 2012;188:5020-5031.
83. + memory T cells correlate with a favorable outcome of tuberculosis. J Infect Dis 2006;194:984-992.
84. Han Q, Bagheri N, Bradshaw EM, Hafler DA, Lauffenburger DA, Love JC. Polyfunctional responses by human T cells result from sequential release of cytokines. Proc Natl Acad Sci USA 2012;109:1607-1612.
85. Kaveh DA, Whelan AO, Hogarth PJ. The duration of antigen-stimulation significantly alters the diversity of multifunctional CD4 T cells measured by intracellular cytokine staining. PLoS ONE 2012;7:e38926.
86. Acosta-Rodriguez EV, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:639-646.
87. + Th1 subset. PLoS Pathog 2013;9:e1003130.
88. Smith SM, et al. Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia. Infect Immun 2000;68:7144-7148.
89. + T cells at the site of infection in human chronic pulmonary tuberculosis. Infect Immun 2007;75:5210-5222.
90. + T cells express CD69. Tuberculosis 2014;94:219-225.
91. Caccamo N, et al. Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS ONE 2009;4:e5528.
92. + T-cell immune response in South African patients with active tuberculosis. PLoS ONE 2013;8:e58309.
93. Day CL, et al. Patients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic phenotype and impaired proliferative capacity, which is not restored following treatment. PLoS ONE 2014;9:e94949.
94. + T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009;119:1167-1177.
95. Gaffen SL, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014;14:585-600.
96. Khader SA, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005;175:788-795.
97. Umemura M, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007;178:3786-3796.
98. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006;177:4662-4669.
99. Okamoto Yoshida Y, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010;184:4414-4422.
100. Cruz A, et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol 2006;177:1416-1420.
101. Desvignes L, Ernst JD. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 2009;31:974-985.
102. Freches D, Korf H, Denis O, Havaux X, Huygen K, Romano M. Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. Immunology 2013;140:220-231.
103. Gopal R, et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog 2014;10:e1004099.
104. + T cells in active disease. Eur J Immunol 2013;43:939-948.
105. + T Cells. Am J Respir Crit Care Med 2010;181:734-742.
106. Hur YG, et al. Combination of cytokine responses indicative of latent TB and active TB in Malawian adults. PLoS ONE 2013;8:e79742.
107. + T cells in latently infected individuals and patients with active TB. Tuberculosis 2013;93:155-166.
108. Cowan J, Pandey S, Filion LG, Angel JB, Kumar A, Cameron DW. Comparison of interferon-gamma-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. Clin Exp Immunol 2012;167:317-329.
109. Bandaru A, et al. Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection. Eur J Immunol 2014;44:2013-2024.
110. Peng MY, et al. Interleukin 17-producing gamma delta T cells increased in patients with active pulmonary tuberculosis. Cell Mol Immunol 2008;5:203-208.
111. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS ONE 2010;5:e12365.
112. Marin ND, Paris SC, Velez VM, Rojas CA, Rojas M, Garcia LF. Regulatory T cell frequency and modulation of IFN-gamma and IL-17 in active and latent tuberculosis. Tuberculosis 2010;90:252-261.
113. + T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008;180:1962-1970.
114. Jurado JO, et al. IL-17 and IFN-gamma expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J Leukoc Biol 2012;91:991-1002.
115. Loxton AG, Black GF, Stanley K, Walzl G. Heparin-binding hemagglutinin induces IFN-gamma(+) IL-2(+) IL-17(+) multifunctional CD4(+) T cells during latent but not active tuberculosis disease. Clin Vaccine Immunol 2012;19:746-751.
116. + regulatory T cells control Leishmania major persistence and immunity. Nature 2002;420:502-507.
117. + regulatory T cells. Nat Immunol 2003;4:330-336.
118. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
119. Pang H, et al. Frequency of regulatory T-cells in the peripheral blood of patients with pulmonary tuberculosis from shanxi province, china. PLoS ONE 2013;8:e65496.
120. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006;173:803-810.
121. + T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 2006;144:25-34.
122. Chen X, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol 2007;123:50-59.
123. He XY, et al. T regulatory cells and Th1/Th2 cytokines in peripheral blood from tuberculosis patients. Eur J Clin Microbiol Infect Dis 2010;29:643-650.
124. + regulatory t cells in the granulomatous lesions. Am J Pathol 2009;174:2211-2224.
125. Kursar M, et al. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J Immunol 2007;178:2661-2665.
126. + transforming growth factor-beta-producing T cells are present in the lung in murine tuberculosis and may regulate the host inflammatory response. Clin Exp Immunol 2007;148:537-545.
127. Scott-Browne JP, et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med 2007;204:2159-2169.
128. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 2010;207:1409-1420.
129. Green AM, Mattila JT, Bigbee CL, Bongers KS, Lin PL, Flynn JL. CD4(+) regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection. J Infect Dis 2010;202:533-541.
130. + T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB. J Immunol 2012;188:4278-4288.
131. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-1232.
132. Chiacchio T, et al. Characterization of regulatory T cells identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis. Clin Exp Immunol 2009;156:463-470.
133. + T cells with an immunosuppressive phenotype are higher in active tuberculosis than latent tuberculosis infection. Tuberculosis 2014;94:494-501.
134. de Cassan SC, et al. Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A. Clin Vaccine Immunol 2010;17:1066-1073.
135. Griffiths KL, et al. Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. PLoS ONE 2011;6:e23463.
136. de Waal Malefyt R, Abrams J, Bennett B, Figdor C, Vries J. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
137. de Waal Malefyt R, et al. IL-10 and v-IL-10 strongly reduce antigen specific human T cell responses by diminishing the antigen presenting capacity of monocytes via down-regulation of class II MHC expression. J Exp Med 1991;174:915-924.
138. Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992;148:3133-3139.
139. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the upregulation of B7 expression. J Immunol 1993;151:1224-1234.
140. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-3822.
141. Fiorentino DF, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146:3444-3451.
142. Mayer-Barber KD, et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011;35:1023-1034.
143. McNab FW, et al. Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-gamma for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages. J Immunol 2014;193:3600-3612.
144. Chegou NN, et al. Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting. PLoS ONE 2013;8:e64226.
145. Phalane KG, et al. Differential expression of host biomarkers in saliva and serum samples from individuals with suspected pulmonary tuberculosis. Mediators Inflamm 2013;2013:981984.
146. Djoba Siawaya JF, et al. Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. Cytokine 2009;47:132-136.
147. Elkington P, et al. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest 2011;121:1827-1833.
148. Jacobsen M, et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 2007;85:613-621.
149. Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-977.
150. Maertzdorf J, et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 2011;6:e26938.
151. Maertzdorf J, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011;12:15-22.
152. Mistry R, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 2007;195:357-365.
153. Bloom CI, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE 2013;8:e70630.
154. Anderson ST, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 2014;370:1712-1723.
155. Stanley SA, Johndrow JE, Manzanillo P, Cox JS. The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol 2007;178:3143-3152.
156. Ordway D, et al. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol 2007;179:522-531.
157. Manca C, et al. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 2005;25:694-701.
158. Manca C, et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci USA 2001;98:5752-5757.
159. Antonelli LR, et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 2010;120:1674-1682.
160. Dorhoi A, et al. Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur J Immunol 2014;44:2380-2393.
161. Redford PS, et al. Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J Infect Dis 2014;209:270-274.
162. Mayer-Barber KD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014;511:99-103.
163. Desvignes L, Wolf AJ, Ernst JD. Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J Immunol 2012;188:6205-6215.
164. Teles RM, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 2013;339:1448-1453.
165. Maertzdorf J, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci USA 2012;109:7853-7858.
166. Ottenhoff TH, et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 2012;7:e45839.
167. Geldmacher C, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 2010;207:2869-2881.
168. Geldmacher C, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008;198:1590-1598.
169. Juffermans NP, et al. Patients with active tuberculosis have increased expression of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells. Clin Infect Dis 2001;32:650-652.
170. Shalekoff S, Pendle S, Johnson D, Martin DJ, Tiemessen CT. Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 on leukocytes of persons with human immunodeficiency virus type 1 infection and pulmonary tuberculosis: implications for pathogenesis. J Clin Immunol 2001;21:390-401.
171. + T-lymphocytes in the course of active pulmonary tuberculosis. Eur Respir J 2004;24:638-643.
172. Rosas-Taraco AG, Arce-Mendoza AY, Caballero-Olin G, Salinas-Carmona MC. Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. AIDS Res Hum Retroviruses 2006;22:45-51.
173. + T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients. J Acquir Immune Defic Syndr 2005;39:265-271.
174. + T lymphocyte population or to restore the depleted naive population in chronically HIV-infected individuals with active pulmonary tuberculosis. AIDS Res Hum Retroviruses 2013;29:769-777.
175. + T cell expansion and increased IL-10 levels. J Immunol 2004;172:1953-1959.
176. Ranjbar S, Boshoff HI, Mulder A, Siddiqi N, Rubin EJ, Goldfeld AE. HIV-1 replication is differentially regulated by distinct clinical strains of Mycobacterium tuberculosis. PLoS ONE 2009;4:e6116.
177. Day JH, et al. Does tuberculosis increase HIV load? J Infect Dis 2004;190:1677-1684.
178. Barnabas RV, Webb EL, Weiss HA, Wasserheit JN. The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis. AIDS 2011;25:1559-1573.
179. Day CL, et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis 2008;197:990-999.
180. Sutherland JS, et al. Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment. J Immunol 2010;184:6537-6544.
181. Kalsdorf B, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 2009;180:1262-1270.
182. + T cell responses to respiratory antigens are impaired in HIV-infected adults. Thorax 2011;66:375-382.
183. Jambo KC, et al. Asymptomatic HIV-infected Individuals on Antiretroviral Therapy Exhibit Impaired Lung CD4(+) T-Cell Responses to Mycobacteria. Am J Respir Crit Care Med 2014;190:938-947.
184. Lahey T, et al. Interferon gamma responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis 2010;202:1265-1272.
185. Diedrich CR, et al. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS ONE 2010;5:e9611.
186. Mattila JT, Diedrich CR, Lin PL, Phuah J, Flynn JL. Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J Immunol 2011;186:3527-3537.
187. Lai RP, Nakiwala JK, Meintjes G, Wilkinson RJ. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 2013;43:1995-2002.
188. Bourgarit A, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. Aids 2006;20:F1-F7.
189. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med 2009;30:797-810.
190. Elliott JH, et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009;200:1736-1745.
191. Vignesh R, et al. TB-IRIS after initiation of antiretroviral therapy is associated with expansion of preexistent Th1 responses against Mycobacterium tuberculosis antigens. J Acquir Immune Defic Syndr 2013;64:241-248.
192. Bourgarit A, et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J Immunol 2009;183:3915-3923.
193. + T cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2014;28:1593-1602.
194. Blanc FX, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-1481.
195. Haridas V, et al. TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB. AIDS 2015;29:263-273.
196. Soares AP, et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008;180:3569-3577.
197. Soares AP, et al. Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis 2013;207:1084-1094.
198. + T cell response. J Immunol 2006;177:5647-5651.
199. Lutwama F, et al. Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants. J Infect Dis 2014;209:887-897.
200. Kagina BM, et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine 2009;27:5488-5495.
201. Pathan AA, et al. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE 2007;2:e1052.
202. O'Garra A, et al. The immune response in tuberculosis. Annu Rev Immunol 2013;31:475-527.
203. + T cells in adults. Am J Respir Crit Care Med 2010;181:1407-1417.
204. Day CL, et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013;188:492-502.
205. + T cells. Eur J Immunol 2010;40:279-290.
206. Grode L, Ganoza CA, Brohm C, Weiner J 3rd, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013;31:1340-1348.
207. Tameris MD, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-1028.
208. Gold MC, et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J Exp Med 2014;211:1601-1610.
209. Joosten SA, et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog 2010;6:e1000782.
210. Spencer CT, et al. Granzyme A produced by gamma(9)delta(2) T cells induces human macrophages to inhibit growth of an intracellular pathogen. PLoS Pathog 2013;9:e1003119.